RT Journal Article
SR Electronic
T1 Complement activation induces excessive T cell cytotoxicity in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.08.21258481
DO 10.1101/2021.06.08.21258481
A1 Georg, Philipp
A1 Astaburuaga-García, Rosario
A1 Bonaguro, Lorenzo
A1 Brumhard, Sophia
A1 Michalick, Laura
A1 Lippert, Lena J.
A1 Kostevc, Tomislav
A1 Gäbel, Christiane
A1 Schneider, Maria
A1 Streitz, Mathias
A1 Demichev, Vadim
A1 Gemünd, Ioanna
A1 Barone, Matthias
A1 Tober-Lau, Pinkus
A1 Helbig, Elisa Theresa
A1 Stein, Julia
A1 Dey, Hannah-Philine
A1 Paclik, Daniela
A1 Mülleder, Michael
A1 Aulakh, Simran Kaur
A1 Mei, Henrik E.
A1 Schulz, Axel R.
A1 Hippenstiel, Stefan
A1 Corman, Victor Max
A1 Beule, Dieter
A1 Wyler, Emanuel
A1 Landthaler, Markus
A1 Obermayer-Wasserscheid, Benedikt
A1 Boor, Peter
A1 Demir, Münevver
A1 Wesselmann, Hans
A1 Suttorp, Norbert
A1 Uhrig, Alexander
A1 Müller-Redetzky, Holger
A1 Nattermann, Jacob
A1 Kuebler, Wolfgang M.
A1 Meisel, Christian
A1 Ralser, Markus
A1 Schultze, Joachim L.
A1 Aschenbrenner, Anna C.
A1 Thibeault, Charlotte
A1 Kurth, Florian
A1 Sander, Leif-Erik
A1 Blüthgen, Nils
A1 Sawitzki, Birgit
YR 2021
UL http://medrxiv.org/content/early/2021/06/11/2021.06.08.21258481.abstract
AB Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathogenesis, and it remains unclear if T cells also contribute to disease pathology. Here, we combined single-cell transcriptomics and proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated, CD16+ T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16+ T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16+ T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Age-dependent generation of C3a in severe COVID-19 induced activated CD16+ cytotoxic T cells. The proportion of activated CD16+ T cells and plasma levels of complement proteins upstream of C3a correlated with clinical outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.Competing Interest StatementV.M.C. is named together with Euroimmun GmbH on a patent application filed recently regarding SARS-CoV-2 diagnostics via antibody testing. A.R.S. and H.E.M. are listed as inventors on a patent application by the DRFZ Berlin in the field of mass cytometry. Funding StatementThis work was supported by the German Research Foundation (DFG): SA1383/3-1 to B.S.; SFB-TR84 114933180 to L.E.S., S.B., P.G., S.H. and W.M.K. INST 37/1049-1, INST 216/981-1, INST 257/605-1, INST 269/768-1, INST 217/988-1, INST 217/577-1, and EXC2151-390873048 to J.L.S.; GRK 2168 - 272482170, ERA CVD (00160389 to J.L.S.; SFB 1454 - 432325352 to A.C.A. and J.L.S.; SFB TR57 and SPP1937 to J.N.; GRK2157 to A.-E.S.; and ME 3644/5-1 to H.E.M.; RTG2424 to N.B.; SFB-TRR219 322900939, BO3755/13-1 Project-ID 454024652 to P.B.; the Berlin University Alliance (BUA) (PreEP-Corona grant to L.E.S. and V.M.C.); the Berlin Institute of Health (BIH) (to L.E.S., V.M.C.,B.S. and W.M.K.); Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany (sparse2big to J.L.S.), EU projects SYSCID (733100 to J.L.S.); European Research Council Horizon 2020 (grant agreement No 101001791 to P.B.); the DZIF, Germany (TTU 04.816 and 04.817 to J.N.); the Hector Foundation (M89 to J.N.); the EU projects ONE STUDY (260687), BIO-DrIM (305147) and INsTRuCT (860003) to B.S.); German Registry of COVID-19 Autopsies through Federal Ministry of Health (ZMVI1-2520COR201 to P.B.); Federal Ministry of Education and Research (DEFEAT PANDEMICs, 01KX2021 and STOP-FSGS-01GM1901A to P.B.); the Berlin Senate to German Rheumatism Research Centre (DRFZ); the Berlin Brandenburg School for regenerative Therapies (BSRT) to C.B.; the German Federal Ministry of Education and Research (BMBF) projects RECAST (01KI20337) to B.S., V.M.C., L.E.S and M.R.; VARIPath (01KI2021) to V.M.C.; NUM COVIM (01KX2021) to L.E.S., V.M.C., F.K., J.L.S., J.N. and B.S.; RAPID to and S.H.,; SYMPATH to N.S. and W.M.K.; PROVID to S.H. and W.M.K.; ZissTrans (02NUK047E) to N.B; National Research Node Mass spectrometry in Systems Medicine (MSCoresys) (031L0220A) to M.R. and N.B.; Diet-Body-Brain (DietBB) (01EA1809A) to J.L.S.; the UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Francis Crick Institute through the Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), the Wellcome Trust (FC001134 and IA 200829/Z/16/Z) to M.R.; a Charité 3R project (to B.S., S.H., W.M.K.); and an intramural grant from the Department of Genomics & Immunoregulation at the LIMES Institute to A.C.A.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cohort 1, Institutional Review board of Charite (EA2/066/20) Cohort 2, Institutional Review board of the University Hospital Bonn (073/19 and 134/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw count data of the scRNA-seq experiments are deposited at GEO under the accession number GSE175450.